DHR
32
-6
DAL
84
-3
CMG
66
-4
STZ
52
-6
AON
54
2
FRT
41
-2
SIG
44
-3
NWSA
62
-7
AMT
37
3
ORCL
63
-4
SWKS
38
-2
CVX
43
-3
ISRG
71
-5
NVDA
52
-5
XYL
35
-2
LRCX
37
-9
EFX
30
-8
BA
47
2
HSY
31
-6
LB
30
4
DHR
32
-6
DAL
84
-3
CMG
66
-4
STZ
52
-6
AON
54
2
FRT
41
-2
SIG
44
-3
NWSA
62
-7
AMT
37
3
ORCL
63
-4
SWKS
38
-2
CVX
43
-3
ISRG
71
-5
NVDA
52
-5
XYL
35
-2
LRCX
37
-9
EFX
30
-8
BA
47
2
HSY
31
-6
LB
30
4
Financhill
Back

Reaves Utility Income Fund Vs. Halozyme Therapeutics Industry Stock Comparison

Buy
66

UTG
Reaves Utility Income Fund

Last Price:
33.36
Seasonality Move:
2.73%
Sell
39

HALO
Halozyme Therapeutics

Last Price:
45.65
Seasonality Move:
17.03%
Buy
66
Reaves Utility Income Fund (UTG) is a Buy

Is Reaves Utility Income Fund a Buy, Sell or Hold?

  • The current Reaves Utility Income Fund [UTG] share price is $33.40. The Score for UTG is 66, which is 32% above its historic median score of 50, and infers lower risk than normal.
  • UTG is currently trading in the 60-70% percentile range relative to its historical Stock Score levels.
  • This Score is currently showing a higher than normal reading, suggesting risk levels may be somewhat lower than normal.
Sell
39
Halozyme Therapeutics (HALO) is a Sell

Is Halozyme Therapeutics a Buy, Sell or Hold?

  • The current Halozyme Therapeutics [HALO] share price is $45.65. The Score for HALO is 39, which is 22% below its historic median score of 50, and infers higher risk than normal.
  • HALO is currently trading in the 30-40% percentile range relative to its historical Stock Score levels.
  • This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.

UTG Stock Price Chart

What is Reaves Utility Income Fund's stock price today?

  • The Reaves Utility Income Fund share price today is $33.40
    Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and UTG is experiencing buying pressure, which is a positive indicator for future bullish movement.

HALO Stock Price Chart

What is Halozyme Therapeutics's stock price today?

  • The Halozyme Therapeutics share price today is $45.65
    Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and HALO is experiencing selling pressure, which indicates risk of future bearish movement.

UTG Technical Analysis

Chart Indicators Level Buy or Sell
MACD (12, 26): 0.35 Buy
Relative Strength Index (14 RSI): 60.96 Buy
Chaikin Money Flow: 145542 -
Bollinger Bands Level Buy or Sell
Bollinger Bands (25): (32.26 - 33.26) Buy
Bollinger Bands (100): (28.49 - 32.49) Buy

HALO Technical Analysis

Chart Indicators Level Buy or Sell
MACD (12, 26): -0.02 Sell
Relative Strength Index (14 RSI): 30.2 Sell
Chaikin Money Flow: -7140517 -
Bollinger Bands Level Buy or Sell
Bollinger Bands (25): (49.94 - 58.56) Sell
Bollinger Bands (100): (52.16 - 60.38) Sell

UTG Moving Averages

Moving Averages Level Buy or Sell
8-day SMA: 33.21 Buy
20-day SMA: 32.78 Buy
50-day SMA: 32.3 Buy
200-day SMA: 28.66 Buy
8-day EMA: 33.21 Buy
20-day EMA: 32.85 Buy
50-day EMA: 32.09 Buy
200-day EMA: 29.53 Buy

HALO Moving Averages

Moving Averages Level Buy or Sell
8-day SMA: 57.53 Sell
20-day SMA: 54.48 Sell
50-day SMA: 56.18 Sell
200-day SMA: 48.93 Sell
8-day EMA: 55 Sell
20-day EMA: 55.41 Sell
50-day EMA: 55.64 Sell
200-day EMA: 50.73 Sell

Reaves Utility Income Fund Earnings Growth & UTG Earnings Dates

  • Analysts estimate an earnings decrease this quarter of $0.00 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.00 per share, and a decrease next year of $0.00 per share.

Halozyme Therapeutics Earnings Growth & HALO Earnings Dates

  • Analysts estimate an earnings increase this quarter of $0.21 per share, a decrease next quarter of $0.00 per share, an increase this year of $1.30 per share, and an increase next year of $0.71 per share.

Reaves Utility Income Fund Technical Analysis

Technical Analysis: Buy or Sell?
8-day SMA:
20-day SMA:
50-day SMA:
200-day SMA:
8-day EMA:
20-day EMA:
50-day EMA:
200-day EMA:
MACD (12, 26):
Relative Strength Index (14 RSI):
Bollinger Bands (25):
Bollinger Bands (100):

Halozyme Therapeutics Technical Analysis

Technical Analysis: Buy or Sell?
8-day SMA:
20-day SMA:
50-day SMA:
200-day SMA:
8-day EMA:
20-day EMA:
50-day EMA:
200-day EMA:
MACD (12, 26):
Relative Strength Index (14 RSI):
Bollinger Bands (25):
Bollinger Bands (100):